Source: European Journal of Pharmaceutical Sciences. Unidades: FCFRP, FMRP
Subjects: FARMACOLOGIA, DIABETES MELLITUS, ANTAGONISMO DE DROGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NARDOTTO, Glauco H. B et al. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. European Journal of Pharmaceutical Sciences, v. 109S, p. S108-S115, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2017.05.033. Acesso em: 22 jul. 2024.APA
Nardotto, G. H. B., Lanchote, V. L., Coelho, E. B., & Della Pasqua, O. (2017). Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. European Journal of Pharmaceutical Sciences, 109S, S108-S115. doi:10.1016/j.ejps.2017.05.033NLM
Nardotto GHB, Lanchote VL, Coelho EB, Della Pasqua O. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients [Internet]. European Journal of Pharmaceutical Sciences. 2017 ; 109S S108-S115.[citado 2024 jul. 22 ] Available from: https://doi.org/10.1016/j.ejps.2017.05.033Vancouver
Nardotto GHB, Lanchote VL, Coelho EB, Della Pasqua O. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients [Internet]. European Journal of Pharmaceutical Sciences. 2017 ; 109S S108-S115.[citado 2024 jul. 22 ] Available from: https://doi.org/10.1016/j.ejps.2017.05.033
